Combining Dyad Protonation and Active Site Plasticity in BACE-1 Structure-Based Drug Design

The ability of the BACE-1 catalytic dyad to adopt multiple protonation states and the conformational flexibility of the active site have hampered the reliability of computational screening campaigns carried out on this drug target for Alzheimer's disease. Here, we propose a protocol that, for the first time, combining quantum mechanical calculations, molecular dynamics, and conformational ensemble virtual ligand screening addresses these issues simultaneously. The encouraging results prefigure this approach as a valuable tool for future drug discovery campaigns.

[1]  R. Silvestri.  Boom in the Development of Non‐Peptidic β‐Secretase (BACE1) Inhibitors for the Treatment of Alzheimer′s Disease , 2009 .

[2]  A. Caflisch,et al.  Functional Plasticity in the Substrate Binding Site of β-Secretase , 2005 .

[3]  G. McGaughey,et al.  Structure-guided design of β-secretase (BACE-1) inhibitors , 2007, Expert opinion on drug discovery.

[4]  Maxim Totrov,et al.  Atomic Property Fields: Generalized 3D Pharmacophoric Potential for Automated Ligand Superposition, Pharmacophore Elucidation and 3D QSAR , 2007, Chemical biology & drug design.

[5]  György M. Keserü,et al.  Ensemble Docking into Flexible Active Sites. Critical Evaluation of FlexE against JNK-3 and beta-Secretase , 2006, J. Chem. Inf. Model..

[6]  R. Abagyan,et al.  Systematic Exploitation of Multiple Receptor Conformations for Virtual Ligand Screening , 2011, PloS one.

[7]  D. Small,et al.  Is BACE1 a suitable therapeutic target for the treatment of Alzheimer's disease? Current strategies and future directions , 2010, Biological chemistry.

[8]  D. Rich,et al.  Designing non-peptide peptidomimetics in the 21st century: inhibitors targeting conformational ensembles. , 2002, Journal of medicinal chemistry.

[9]  Christopher I. Bayly,et al.  Evaluating Virtual Screening Methods: Good and Bad Metrics for the "Early Recognition" Problem , 2007, J. Chem. Inf. Model..

[10]  Gyoergy M. Keserue,et al.  Ensemble Docking into Flexible Active Sites. Critical Evaluation of FlexE Against JNK-3 and β-Secretase. , 2006 .

[11]  Amedeo Caflisch,et al.  On the orientation of the catalytic dyad in aspartic proteases , 2010, Proteins.

[12]  R. J. Kelleher,et al.  γ-Secretase and Human Disease , 2010, Science.

[13]  Erik Lindström,et al.  Effect of the protonation state of the titratable residues on the inhibitor affinity to BACE-1. , 2010, Biochemistry.

[14]  M. Citron.  Alzheimer's disease: strategies for disease modification , 2010, Nature Reviews Drug Discovery.

[15]  Ruben Abagyan,et al.  Recipes for the Selection of Experimental Protein Conformations for Virtual Screening , 2010, J. Chem. Inf. Model..

[16]  Yongzhou Hu,et al.  Progress in the development of nonpeptidomimetic BACE 1 inhibitors for Alzheimer's disease. , 2009, Current medicinal chemistry.

[17]  J. Bajorath,et al.  Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.

[18]  Kenneth M Merz,et al.  Assigning the protonation states of the key aspartates in β-Secretase using QM/MM X-ray structure refinement. , 2006, Journal of chemical theory and computation.

[19]  Migliore Amico.  Ensemble-docking approach on BACE-1 : Pharmacophore Perception and Guidelines for Drug Design , .

[20]  B. Turk.  Targeting proteases: successes, failures and future prospects , 2006, Nature Reviews Drug Discovery.

[21]  Robin Taylor,et al.  Comparing protein–ligand docking programs is difficult , 2005, Proteins.

[22]  L Hong,et al.  Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor. , 2000, Science.

[23]  Hwangseo Park,et al.  Determination of the active site protonation state of beta-secretase from molecular dynamics simulation and docking experiment: implications for structure-based inhibitor design. , 2003, Journal of the American Chemical Society.

[24]  Jonathan W. Essex,et al.  Ensemble Docking into Multiple Crystallographically Derived Protein Structures: An Evaluation Based on the Statistical Analysis of Enrichments , 2010, J. Chem. Inf. Model..

[25]  Charles H. Reynolds,et al.  Modeling the Protonation States of the Catalytic Aspartates in β-Secretase , 2004 .

[26]  Romano Silvestri,et al.  Boom in the development of non‐peptidic β‐secretase (BACE1) inhibitors for the treatment of Alzheimer's disease , 2009, Medicinal research reviews.

[27]  Tímea Polgár,et al.  Virtual screening for beta-secretase (BACE1) inhibitors reveals the importance of protonation states at Asp32 and Asp228. , 2005, Journal of medicinal chemistry.